Use of PLCO data to evaluate the performance of cancer risk models
Principal Investigator
Name
Thomas Ahearn
Degrees
PhD, MPH
Institution
Division of Cancer Genetics and Epidemiology, NCI
Position Title
Staff Scientisst
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-1025
Initial CDAS Request Approval
Aug 22, 2022
Title
Use of PLCO data to evaluate the performance of cancer risk models
Summary
In this project we will use PLCO data to evaluate the performance of cancer risk models. We will use data collected on the baseline questionnaire (BQ) to prospectively evaluate cancer risk models for: Breast, Lung and bronchus, Prostate, Colorectal, Melanoma of the skin, Urinary bladder, Non-Hodgkin lymphoma, Kidney and renal pelvis, Uterine corpus, Leukemia, Pancreas, Oral cavity and pharynx, Thyroid, Liver and intrahepatic bile duct, Myeloma.
In addition to the BQ data, we are also requesting that variables derived for the subset of PLCO study participants participating in the the collaboration with the Breast Cancer Association Consortium (BCAC) be derived for the rest of the PLCO study population.
In addition to the BQ data, we are also requesting that variables derived for the subset of PLCO study participants participating in the the collaboration with the Breast Cancer Association Consortium (BCAC) be derived for the rest of the PLCO study population.
Aims
We will use iCARE (PMID: 31165158) to evaluate the calibration and discrimination of cancer risk models (see list of cancers in Project Summary)
Collaborators
Montserrat Garcia-Closas (DCEG),
Nilanjan Chatterjee (Johns Hopkins University),
Parichoy Pal Choudhury (American Cancer Society),
Jeya Balasubramanian (DCEG),
Srijon Mukopadhyay (DCEG),
Jonas De Almedia (DCEG)